Female Contraception Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update

Powered by

All the vital news, analysis, and commentary curated by our industry experts.

Female Contraception Pipeline Drugs Market Report Overview

Contraception (birth control) prevents pregnancy by interfering with the normal process of ovulation, fertilization, and implantation. There are many contraceptive methods which include implants and injections, intrauterine devices (IUDs), pills and vaginal rings, barrier methods, sterilization, and natural methods.

The Female Contraception pipeline drugs market research report provides comprehensive information on the therapeutics under development for Female Contraception, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA), and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history, and the latest news and press releases. Additionally, the report offers an overview of key players involved in therapeutic development for Female Contraception and features dormant and discontinued projects.

Female Contraception Pipeline Drugs Market Segmentation by Targets

The key targets in the Female Contraception pipeline drugs market are Progesterone Receptor, Estrogen Receptor, Anti Muellerian Hormone Type 2 Receptor, Cation Channel Sperm Associated Protein 1, and others. Progesterone Receptor has the highest number of products in development in the Female Contraception pipeline drugs market in 2022.

Female Contraception Pipeline Drugs Market Analysis by Targets

Female Contraception Pipeline Drugs Market Analysis by TargetsFor more target insights into the Female Contraception pipeline drugs market, download a free report sample

Female Contraception Pipeline Drugs Market Segmentation by Mechanisms of Action

The key mechanisms of action in the Female Contraception pipeline drugs market are Progesterone Receptor Agonist, Estrogen Receptor Agonist, Progesterone Receptor Antagonist, Anti Muellerian Hormone Type 2 Receptor Agonist, and others. Progesterone Receptor Agonist leads the Female Contraception pipeline drugs market in terms of MoA.

Female Contraception Pipeline Drugs Market Analysis by Mechanisms of Action

Female Contraception Pipeline Drugs Market Analysis by Mechanisms of ActionFor more MoA insights into the Female Contraception pipeline drugs market, download a free report sample

Female Contraception Pipeline Drugs Market Segmentation by Routes of Administration

The key routes of administration in the Female Contraception pipeline drugs market are oral, vaginal, transdermal, subcutaneous, topical, parenteral, and buccal. The oral RoA has the highest number of Female Contraception drugs in development in 2022.

Female Contraception Pipeline Drugs Market Analysis by Routes of Administration

Female Contraception Pipeline Drugs Market Analysis by Routes of AdministrationFor more RoA insights into the Female Contraception pipeline drugs market, download a free report sample

Female Contraception Pipeline Drugs Market Segmentation by Molecule Types

The key molecule types in the Female Contraception pipeline drugs market are small molecule, monoclonal antibody, polymer, recombinant protein, and toxoid vaccine. Small molecule leads the Female Contraception pipeline drugs market in terms of molecule type.

Female Contraception Pipeline Drugs Market Analysis by Molecule Types

Female Contraception Pipeline Drugs Market Analysis by Molecule TypesFor more molecule type insights into the Female Contraception drugs market, download a free report sample

Female Contraception Pipeline Drugs Market - Competitive Landscape

Some of the leading companies in the Female Contraception pipeline drugs market are Evestra Inc, Agile Therapeutics Inc, Viramal Ltd, and Adare Pharma Solutions. Evestra Inc accounted for the highest number of Female Contraception pipeline drugs in 2022.

Female Contraception Pipeline Drugs Market Analysis by Companies

Female Contraception Pipeline Drugs Market Analysis by CompaniesTo know more about the leading Female Contraception pipeline drugs market players, download a free report sample

Female Contraception Pipeline Products Market Overview

Key Targets Progesterone Receptor, Estrogen Receptor, Anti Muellerian Hormone Type 2 Receptor, Cation Channel Sperm Associated Protein 1, and Others
Key Mechanisms of Action Progesterone Receptor Agonist, Estrogen Receptor Agonist, Progesterone Receptor Antagonist, Anti Muellerian Hormone Type 2 Receptor Agonist, and Others
Key Routes of Administration Oral, Vaginal, Transdermal, Subcutaneous, Topical, Parenteral, and Buccal
Key Molecule Type Small Molecule, Monoclonal Antibody, Polymer, Recombinant Protein, and Toxoid Vaccine
Leading Companies Evestra Inc, Agile Therapeutics Inc, Viramal Ltd, Adare Pharma Solutions, and Others.

Scope

  • The pipeline guide provides a snapshot of the global therapeutic landscape of Female Contraception.
  • The pipeline guide reviews pipeline therapeutics for Female Contraception by companies and universities/research institutes based on information derived from company and industry-specific sources.
  • The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
  • The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
  • The pipeline guide reviews key companies involved in Female Contraception therapeutics and enlists all their major and minor projects.
  • The pipeline guide evaluates Female Contraception therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA), and molecule type.
  • The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
  • The pipeline guide reviews the latest news related to pipeline therapeutics for Female Contraception

Reasons to Buy

  • Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
  • Recognize emerging players with potentially strong product portfolios and create effective counter-strategies to gain competitive advantage.
  • Find and recognize significant and varied types of therapeutics under development for Female Contraception.
  • Classify potential new clients or partners in the target demographic.
  • Develop tactical initiatives by understanding the focus areas of leading companies.
  • Plan mergers and acquisitions meritoriously by identifying key players and their most promising pipeline therapeutics.
  • Formulate corrective measures for pipeline projects by understanding the Female Contraception pipeline depth and focus of Indication therapeutics.
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
  • Adjust the therapeutic portfolio by recognizing discontinued projects and understanding from the know-how what drove them from the pipeline.

Adare Pharma Solutions
Agile Therapeutics Inc
Dare Bioscience Inc
Evestra Inc
Evofem Biosciences Inc
Exeltis Pharmaceuticals Holding SL
Hervana Ltd
Hyundai Pharma Co Ltd
InSilico Medicine
Insud Pharma
Lyndra Therapeutics Inc.
MedinCell SA
Micron Biomedical Inc
Mithra Pharmaceuticals SA
Mucommune LLC
Myovant Sciences Ltd
Navad Life Sciences Pte Ltd
Noven Pharmaceuticals Inc
Ohana BioSciences Inc
Organon & Co
Orion Biotechnology Canada Ltd
Schrodinger Inc
Teva Pharmaceutical Industries Ltd
Viramal Ltd
Yaso Therapeutics Inc
YourChoice Therapeutics Inc
ZabBio Inc

Table of Contents

Table of Contents

List of Tables

List of Figures

Introduction

Global Markets Direct Report Coverage

Female Contraception – Overview

Female Contraception – Therapeutics Development

Pipeline Overview

Pipeline by Companies

Pipeline by Universities/Institutes

Products under Development by Companies

Products under Development by Universities/Institutes

Female Contraception – Therapeutics Assessment

Assessment by Target

Assessment by Mechanism of Action

Assessment by Route of Administration

Assessment by Molecule Type

Female Contraception – Companies Involved in Therapeutics Development

Female Contraception – Drug Profiles

Female Contraception – Dormant Projects

Female Contraception – Discontinued Products

Female Contraception – Product Development Milestones

Featured News & Press Releases

Oct 26, 2022: Phexxi mechanism of action article published in the Journal of Therapeutic Advances in Reproductive Health

Oct 24, 2022: Mithra and Fuji announce approval of NEXTSTELLIS in Thailand

Oct 06, 2022: Evofem Biosciences announces approval of Phexxi in Nigeria

Sep 21, 2022: Mithra and Lotus announce approval of ALYSSA, an innovative oral contraceptive, in both Taiwan and Hong Kong

Sep 19, 2022: Inventor of the year awarded to developer of Phexxi

Sep 16, 2022: Large Commercial payer adds Phexxi to formulary for standard plans nationwide

Aug 02, 2022: Nextstellis oral contraceptive has been nominated for the 2022 Prix Galien USA award for best pharmaceutical agent

Aug 01, 2022: Mithra Announces Mayne Pharma’s New Direct-to-Consumer Campaign to Further Increase Awareness of NEXTSTELLIS in the U.S.

Jul 29, 2022: Mayne Pharma and GoodRx announce new initiative to increase awareness of NEXTSTELLIS and expand access to birth control

Jul 26, 2022: NEXTSTELLIS oral contraceptive now available in Australia

Jul 26, 2022: Evofem’s House Rules Campaign featuring Annie Murphy receives Significant Industry Recognition

Jun 30, 2022: Evofem strengthens Phexxi intellectual property with new composition of matter patent from USPTO

Jun 16, 2022: Phexxi prevented 99% of pregnancies per act of intercourse in a post hoc analysis of phase 3 AMPOWER Clinical Trial Data

May 10, 2022: Evofem Biosciences to decrease cost of goods 45 percent through new partnership with Bora Pharmaceutical Services for the commercial manufacturing of Phexxi

Apr 19, 2022: Journal of Sexual Medicine Publishes Sexual Satisfaction Data Involving Phexxi from Evofem’s Phase 3 AMPOWER Clinical Trial

Appendix

Methodology

Coverage

Secondary Research

Primary Research

Expert Panel Validation

Contact Us

Disclaimer

Table

List of Tables

Number of Products under Development for Female Contraception, 2022

Number of Products under Development by Companies, 2022

Number of Products under Development by Companies, 2022 (Contd..1)

Number of Products under Development by Universities/Institutes, 2022

Products under Development by Companies, 2022

Products under Development by Companies, 2022 (Contd..1)

Products under Development by Companies, 2022 (Contd..2)

Products under Development by Universities/Institutes, 2022

Number of Products by Stage and Target, 2022

Number of Products by Stage and Mechanism of Action, 2022

Number of Products by Stage and Route of Administration, 2022

Number of Products by Stage and Molecule Type, 2022

Female Contraception – Dormant Projects, 2022

Female Contraception – Dormant Projects, 2022 (Contd..1)

Female Contraception – Discontinued Products, 2022

Figures

List of Figures

Number of Products under Development for Female Contraception, 2022

Number of Products under Development by Companies, 2022

Number of Products under Development by Universities/Institutes, 2022

Number of Products by Top 10 Targets, 2022

Number of Products by Stage and Top 10 Targets, 2022

Number of Products by Top 10 Mechanism of Actions, 2022

Number of Products by Stage and Top 10 Mechanism of Actions, 2022

Number of Products by Top 10 Routes of Administration, 2022

Number of Products by Stage and Top 10 Routes of Administration, 2022

Number of Products by Top 10 Molecule Types, 2022

Number of Products by Stage and Top 10 Molecule Types, 2022

Frequently asked questions

Female Contraception Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update thematic reports
Currency USD
$2,000

Can be used by individual purchaser only

$6,000

Can be shared globally by unlimited users within the purchasing corporation e.g. all employees of a single company


Undecided about purchasing this report?

Enquire Before Buying Request a Free Sample

Get in touch to find out about multi-purchase discounts

reportstore@globaldata.com
Tel +44 20 7947 2745

Every customer’s requirement is unique. With over 220,000 construction projects tracked, we can create a tailored dataset for you based on the types of projects you are looking for. Please get in touch with your specific requirements and we can send you a quote.

Sample Report

Female Contraception Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update was curated by the best experts in the industry and we are confident about its unique quality. However, we want you to make the most beneficial decision for your business, so we offer free sample pages to help you:

  • Assess the relevance of the report
  • Evaluate the quality of the report
  • Justify the cost

Download your copy of the sample report and make an informed decision about whether the full report will provide you with the insights and information you need.

Below is a sample report to understand what you are buying

See what our customers are saying

“The GlobalData platform is our go-to tool for intelligence services. GlobalData provides an easy way to access comprehensive intelligence data around multiple sectors, which essentially makes it a one-for-all intelligence platform, for tendering and approaching customers.

GlobalData is very customer orientated, with a high degree of personalised services, which benefits everyday use. The highly detailed project intelligence and forecast reports can be utilised across multiple departments and workflow scopes, from operational to strategic level, and often support strategic decisions. GlobalData Analytics and visualisation solutions has contributed positively when preparing management presentations and strategic papers.”

Business Intelligence & Marketing Manager, SAL Heavy Lift

“COVID-19 has caused significant interference to our business and the COVID-19 intelligence from GlobalData has helped us reach better decisions around strategy. These two highlights have helped enormously to understand the projections into the future concerning our business units, we also utilise the project database to source new projects for Liebherr-Werk to use as an additional source to pitch for new business.”

Market Analyst & Management, Liebherr-Werk

Your daily news has saved me a lot of time and keeps me up-to-date with what is happening in the market, I like that you almost always have a link to the source origin. We also use your market data in our Strategic Business Process to support our business decisions. By having everything in one place on the Intelligence Center it has saved me a lot of time versus looking on different sources, the alert function also helps with this.

Head of Key Accounts, Saab AB

Having used several other market research companies, I find that GlobalData manages to provide that ‘difficult-to-get’ market data that others can’t, as well as very diverse and complete consumer surveys.

Marketing Intelligence Manager, Portugal Foods

Our experience with GlobalData has been very good, from the platform itself to the people. I find that the analysts and the account team have a high level of customer focus and responsiveness and therefore I can always rely on. The platform is more holistic than other providers. It is convenient and almost like a one stop shop. The pricing suite is highly competitive and value for our organisation.

I like reports that inform new segments such as the analysis on generation Z, millennials, the impact of COVID 19 to our banking customers and their new channel habits. Secondly the specialist insight on affluent sector significantly increases our understanding about this group of customers. The combination of those give us depth and breadth of the evolving market.

I’m in the business of answering and helping people make decisions so with the intelligence center I can do that, effectively and efficiently. I can share quickly key insights that answer and satisfy our country stakeholders by giving them many quality studies and primary research about competitive landscape beyond the outlook of our bank. It helps me be seen as an advisory partner and that makes a big difference. A big benefit of our subscription is that no one holds the whole data and because it allows so many people, so many different parts of our organisation have access, it enables all teams to have the same level of knowledge and decision support.

Head of Customer Insight and Research, Standard Chartered

“I know that I can always rely on Globaldata’s work when I’m searching for the right consumer and market insights. I use Globaldata insights to understand the changing market & consumer landscape and help create better taste & wellbeing solutions for our customers in food, beverage and healthcare industries.

Globaldata has the right data and the reports are of very high quality compared to your competitors. Globaldata not only has overall market sizes & consumer insights on food & beverages but also provides insights at the ingredient & flavour level. That is key for B2B companies like Givaudan. This way we understand our customers’ business and also gain insight to our unique industry”

Head of Consumer Sensory Insights, Givaudan

GlobalData provides a great range of information and reports on various sectors that is highly relevant, timely, easy to access and utilise.  The reports and data dashboards help engagement with clients; they provide valuable industry and market insights that can enrich client conversations and can help in the shaping of value propositions. Moreover, using GlobalData products has helped increase my knowledge of the finance sector, the players within it, and the general threats and opportunities.

I find the consumer surveys that are carried out to be extremely beneficial and not something I have seen anywhere else. They provided an insightful view of why and which consumers take (or don’t) particular financial products. This can help shape conversations with clients to ensure they make the right strategic decisions for their business.

One of the challenges I have found is that data in the payments space is often piecemeal. With GD all of the data I need is in one place, but it also comes with additional market reports that provide useful extra context and information. Having the ability to set-up alerts on relevant movements in the industry, be it competitors or customers, and have them emailed directly to me, ensures I get early sight of industry activity and don’t have to search for news.

Senior Account Manager, TSYS
Go even deeper with GlobalData Intelligence Center

Every Company Report we produce is powered by the GlobalData Intelligence Center.

Subscribing to our intelligence platform means you can monitor developments at Female Contraception Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update in real time.

  • Access a live Female Contraception Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update dashboard for 12 months, with up-to-the-minute insights.
  • Fuel your decision making with real-time deal coverage and media activity.
  • Turn insights on financials, deals, products and pipelines into powerful agents of commercial advantage.